Streetbeat News

Products Services

KUKE

Kuke Music Holding Limited (NYSE: KUKE) has announced a partnership with Shanghai Jidou Science and Technology Co., Ltd. to integrate its AI music technology into automobiles. This collaboration will see Kuke's AI music application launched in Jidou's car application store, enhancing the in-car music experience for users.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:22 pm

LXRX

Lexicon Pharmaceuticals (NASDAQ:LXRX) announced three poster presentations on diabetic peripheral neuropathic pain at the 84th Scientific Sessions of the American Diabetes Association, taking place from June 21-24, 2024, in Orlando, Florida.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:15 pm

COST

JDST

JNUG

Direxion's Junior Gold Miners Bull (JNUG) and Bear (JDST) ETFs are in focus due to contrasting performances. JNUG lost over 4% while JDST gained nearly 4%. The gold market has been volatile, influenced by inflation concerns and Federal Reserve policies. JNUG is showing signs of a bearish pattern, while JDST is showing potential for a rise.

Portfolio Pulse from Joshenomoto@benzinga.com

June 14, 2024 | 12:11 pm

AMZN

CMCSA

DIS

NFLX

PARA

Netflix is seeking a production partner for NFL games it plans to air on Christmas Day, as well as in 2025 and 2026. The company is in discussions with major broadcasters like Disney, Comcast, and Paramount Global. This marks Netflix's first significant venture into live sports, aiming to expand its advertising tier.

Portfolio Pulse from Benzinga Neuro

June 14, 2024 | 12:07 pm

MBRX

Moleculin Biotech, Inc. (MBRX) reported additional preliminary interim data from its AML clinical trial, showing promising results in subjects with poor prognosis cytogenetics and/or mutations. The trial demonstrated a median durability of response of 6 months and increasing, with significant survival rates and no cardiotoxicity. The data was presented at the European Hematology Association 2024 Hybrid Congress.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:05 pm

JSPR

Jasper Therapeutics presented preclinical data on Briquilimab at the 2024 EHA Hybrid Congress, showcasing promising results.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:04 pm

JNJ

Johnson & Johnson has reported long-term data from its Phase 1/2 Monumental-1 study, which could have significant implications for the company's future product offerings and market position.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:04 pm

TAK

Takeda has signed an option agreement with Ascentage Pharma for the exclusive license of Olverembatinib, a potential third-generation BCR-ABL TKI for CML and other hematological cancers. The license excludes Mainland China, Hong Kong, Macau, Taiwan, and Russia. Takeda will receive the exclusive option to license global rights to Olverembatinib in all other territories. Ascentage Pharma will advance late-stage clinical development of Olverembatinib before Takeda potentially exercises the option.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:02 pm

MOLN

Molecular Partners shares are trading higher after the company announced preclinical proof-of-concept data from MP0621.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 12:00 pm

BPTH

Bio-Path Holdings shares are trading higher following the announcement of positive interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for treating acute myeloid leukemia.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:54 am